Events

Medical Device Connectivity: HIPAA, FDA and IP Considerations

Events / Wednesday, June 14, 2017

On Wednesday, June 14, 2017, BakerHostetler hosted a complimentary CLE webinar: Medical Device Connectivity: HIPAA, FDA and IP Considerations

With increasing healthcare costs and the transition to value-based reimbursement, never has the need for connected medical devices been so great – and never have the pitfalls been so daunting. Join us for an overview of the regulatory and intellectual property landscape for this groundbreaking technology.

Our speakers summarized developments in compliance and security issues, FDA guidelines for premarket and postmarket management of cybersecurity, as well as FDA rules regarding software for medical devices and software as a medical device (SaMD).

In addition, IP considerations such as claim drafting strategies, design patents for GUIs and recommendations for layered protection of patient monitoring inventions were also discussed.

Presented by:
  • Hussein Akhavannik focuses his practice on portfolio management, patent prosecution and IP due diligence. He prosecutes patent applications in technologies related to the electrical, computer, medical and mechanical arts. Hussein spent almost four years at the U.S. Patent and Trademark Office as a patent examiner and as a legal intern for the Patent Trial and Appeal Board and the Office of the Solicitor.
  • With a background as a defense, regulatory, and registered patent attorney who has also worked as a registered pharmacist, Lee Rosebush provides his clients with legal counsel that is grounded in first-hand experience. Lee is frequently sought out to help expedite corporate deals involving healthcare entities.
Presentation Materials >>
Recording

For questions, contact Natalia Egan at 216.430.2941.

Related Industries

Blog

In The Blogs

Previous Next
Health Law Update
Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products
May 15, 2023
On May 10, the U.S. Food and Drug Administration (FDA) published a discussion paper, “Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products.” The paper is a collaboration between FDA’s Center for...
Read More ->
Health Law Update
Supreme Court Orders That Mifepristone Remain Widely Available Pending Appeal in Fifth Circuit
By Amy E. Fouts, Scott P. Robertson
April 25, 2023
On Friday, April 7, the Northern District of Texas issued a decision blocking the prescribing and dispensing of mifepristone nationwide. The court held that plaintiffs had a substantial likelihood of success on the merits regarding their...
Read More ->
Health Law Update
Challenge to the FDA's Approval of Abortion Medication
By Claire M. Bass, Amy E. Fouts
April 17, 2023
On Friday, April 7, both the Northern District of Texas and the Eastern District of Washington issued decisions impacting the FDA approval of the abortion drug mifepristone. The Texas decision blocks prescribing and dispensing of...
Read More ->
Health Law Update
Cybersecurity in Medical Devices
By Laura E. Macherelli, Lee H. Rosebush, Lynn Sessions
April 10, 2023
The U.S. Food and Drug Administration (FDA) has issued new guidance to the medical device industry on the importance of cybersecurity measures in product development. The nonbinding guidance, titled “Cybersecurity in Medical Devices...
Read More ->
Health Law Update
Staying Ahead of the Curve in Biopharma: Navigating FDA Inspections, Drug Supply Chain Security Act (DSCSA) Implementation, and Supply Chain Disruptions
By Winston S. Kirton, Lee H. Rosebush
April 6, 2023
FDA inspections of biopharmaceutical manufacturers often lead to the discovery of avoidable compliance issues. On today’s episode, Staying Ahead of the Curve in BioPharma: Navigating FDA Inspections, Drug Supply Chain Security Act (DSCSA)...
Read More ->